Methods of increasing satellite cell proliferation
US-9248185-B2 · Feb 2, 2016 · US
Methods of increasing satellite cell proliferation with kinase inhibitors
US9782417B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9782417-B2 |
| Application number | US-201615012656-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 1, 2016 |
| Priority date | Jun 16, 2011 |
| Publication date | Oct 10, 2017 |
| Grant date | Oct 10, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention provides methods for inducing, enhancing or increasing satellite cell proliferation, and an assay for screening for a candidate compound for inducing, enhancing or increasing satellite cell proliferation. Also provided are methods for repairing or regenerating a damaged muscle tissue of a subject.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of increasing satellite cell proliferation, the method comprising: contacting a satellite cell with a compound, wherein the compound is selected from the group consisting of SU11652 Sunitinib (SU 11248, Bosutinib (SKI 606, Jak3 Inhibitor V and combinations thereof. 2. The method of claim 1 , wherein the cell is additionally contacted with lestaurtinib (CEP-701). 3. The method of claim 1 , wherein the contacting is in vivo. 4. The method of claim 3 , wherein in vivo contacting is in a human. 5. The method of claim 3 , wherein the in vivo contacting is in a subject, wherein the subject is in need of treatment for damaged muscle tissue. 6. The method of claim 5 , wherein the damaged muscle tissue is the result of a physical injury or accident, disease, infection, over-use, loss of blood circulation, or muscle atrophy or wasting. 7. The method of claim 5 , wherein the damaged muscle tissue is the result of muscle atrophy/wasting. 8. A method for muscle repair or regeneration in a subject, the method comprising administering a therapeutically effective amount of a compound to the subject, which subject has a damaged muscle tissue, and wherein the compound is selected from the group consisting of SU11652, Sunitinib (SU 11248, Bosutinib (SKI 606, Jak3 Inhibitor VI and combinations thereof. 9. The method of claim 8 , wherein the subject is human. 10. The method of claim 8 , wherein the cell is additionally contacted with lestaurtinib (CEP-701).
Assignees
Inventors
Classifications
Drugs for disorders of the muscular or neuromuscular system · CPC title
Anabolic agents (androgens A61P5/26) · CPC title
Amides, e.g. hydroxamic acids · CPC title
without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids · CPC title
Quinolines; Isoquinolines · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9782417B2 cover?
- The invention provides methods for inducing, enhancing or increasing satellite cell proliferation, and an assay for screening for a candidate compound for inducing, enhancing or increasing satellite cell proliferation. Also provided are methods for repairing or regenerating a damaged muscle tissue of a subject.
- Who is the assignee on this patent?
- Harvard College, Presidents And Fellows Of Harvard College
- What technology area does this patent fall under?
- Primary CPC classification A61K31/553. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Oct 10 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).